Wed.Feb 23, 2022

article thumbnail

Takeda grows in gene therapies again with $2bn Code Bio deal

pharmaphorum

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The Japanese drugmaker will get access to Code Bio’s 3DNA non-viral genetic medicine delivery platform, initially for a liver-directed programme, and is also interested in deploying the technology for central nervous system disorders.

article thumbnail

Next Generation Sequencing (NGS) Library Preparation Kits: Revolutionizing the Field of Genetic Sciences

Roots Analysis

NGS has emerged as an evolutionary technology in modern biotechnology and healthcare research, enabling researchers to develop a better understanding of the cause and consequences of disease. Over the past few years, several companies have started offering a diverse range of genome sequencing products and services using various second and third generation sequencing technologies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

5 Situations That Prompt Patients to Engage in Social Health

pharmaphorum

Nothing quite compares to the level of solace patients find in connecting with others who share similar health experiences. These interactions have become so fundamental to people living with chronic conditions that a recent Health Union survey of 2,371 patients revealed 95% use online social resources for health reasons. In 2022, social health – the dynamic, real-time actions people take to find meaningful connections and share information throughout the health journey – is more relevant tha

98
article thumbnail

MAOIs in Parkinson’s – Breakdown For Pharmacists

Med Ed 101

Pharmacists are no strangers to neurodegenerative disease. However, Parkinson’s cases present great difficulty to patients and clinicians, as our medical world lacks a solid understanding of the disease in comparison to other conditions. After Alzheimer’s disease, Parkinson’s is the second most prevalent neurodegenerative disease. It is estimated at least 1 million people in the U.S. […].

40
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Biosimilars: a rapidly maturing market

pharmaphorum

Adoption of biosimilars in the US has been notoriously slow, but biosimilars manufacturers and outside observers expect this to change rapidly in the coming years. Ben Hargreaves takes a look at why uptake began slowly in both the EU and the US, and then began to accelerate to see biosimilars take a large portion of market share away from originator products.

article thumbnail

Greater tolerance: Allergic reactions to COVID vaccine lower for second dose

Pharma Times

Researchers discovered that recipients experiencing an allergic response to second COVID vaccine dose are minimal

More Trending

article thumbnail

Haleon days: GSK explains demerger decision

Pharma Times

New company Haleon will become standalone venture as GSK's strategy for the future unfolds

45
article thumbnail

Judge shuts down Servier’s argument that NHS should have stopped prescribing its drugs

pharmaphorum

A London high court judge ruled this week that the damages paid to the NHS for an anticompetitive action by French pharma company Servier will not be reduced, despite an eyebrow-raising bid by Servier to lower them by arguing against its own product. The decision was a major milestone in the 11-year case that’s set to conclude later this year.

52
article thumbnail

Open Fracture Management: Antibiotics

Pharmacy Friday Pearls

Download PDF. Introduction. Open fracture wounds are considered high energy injuries that come with a high risk of infection due to the potential exposure of bone and tissue to environmental pathogens. The Gustilo- Anderson classification system grades open fractures and can be utilized to guide antimicrobial prophylaxis. For Type I fractures, which are clean wounds less than 1 centimeter long, gram positive coverage is recommended; cefazolin is usually the agent of choice.

40
article thumbnail

AstraZeneca, Honeywell partner to address climate change with new inhaler tech

pharmaphorum

UK-based global pharma company AstraZeneca and US consumer products company Honeywell have announced a partnership to build a new “next generation” inhaler with a propellant that reduces Global Warming Potential by more than 99%. . The deal is part of a broader sustainability initiative by AstraZeneca that also includes an ambitious plan to reduce emissions and move toward sustainable power sources.

52
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

AbbVie files Vraylar as add-on therapy for depression in US

pharmaphorum

AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include adjunctive therapy for major depressive disorder, part of a plan to build sales of the drug to peak sales of $4 billion or more. The company is seeking approval from the US regulator for Vraylar (cariprazine) as an add-on to conventional antidepressant therapy in people with MDD who may be struggling to control symptoms using the antidepressant alone.

article thumbnail

2nd Annual Gene Therapy Patient Engagement Summit

pharmaphorum

As investment in gene therapies continues to grow rapidly, more effectively engaging patients throughout development has become a priority for any company serious about building safer and more meaningful gene therapy programs. In this context, the 2 nd Annual Gene Therapy Patient Engagement Summit will unite patient advocacy and engagement leaders from gene therapy and gene editing drug developers, patient groups and patients themselves to address the specific challenges of genetic therapy

FDA 52
article thumbnail

GSK names its consumer health spinoff Haleon

pharmaphorum

GlaxoSmithKline’s consumer health business will be named Haleon following its planned spinoff and listing on the London Stock Exchange later this year, according to the drugmaker. The name of the unit – whose brands include Sensodyne toothpaste and Voltaren and Panadol painkillers and Centrum multivitamins – comes from the marriage of the word “hale”, meaning healthy, and “leon”, signifying strength.